Placebo tablets BID

DRUG2 trials

Sponsors

Trevi Therapeutics

Conditions

Nodularis PrurigoPrurigoPrurigo NodularisPruritusUremic Pruritus

Phase 2

Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

CompletedNCT02143648

Trevi TherapeuticsPruritus, Uremic Pruritus

Start: 2014-06-30End: 2015-07-31Updated: 2025-05-21

Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis

CompletedNCT02174419

Trevi TherapeuticsNodularis Prurigo, Prurigo, Prurigo Nodularis +1

Start: 2015-03-31End: 2016-08-31Updated: 2025-05-21

Related Papers

A population pharmacokinetic–pharmacodynamic model evaluating efficacy of nalbuphine extended‐release in patients with prurigo nodularis

British Journal of Clinical Pharmacology2023-01-211 citations

Worst itch numerical rating scale for prurigo nodularis: a psychometric evaluation

Journal of the European Academy of Dermatology and Venereology2021-12-1519 citations

Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open‐label extension phase

Journal of the European Academy of Dermatology and Venereology2021-11-1543 citations